Home › Research › Drug development
In Silico Design and Molecular Docking of Dalfina: A Tau-Targeting Small Molecule for Alzheimer's Disease Therapy
Mendis LG.. Authorea Preprints, 2025-06-03
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by abnormal aggregation of the tau protein. In this study, we designed a novel small molecule, Dalfina, through rational drug design and in silico docking simulations. Dalfina was optimized to selectively bind hyperphosphorylated tau isoforms and demonstrated favorable physicochemical properties for blood-brain barrier (BBB) permeability. Molecular docking was performed using Autodock Vina and revealed binding affinities ranging from-5.1 to-6.2 kcal/mol at key allosteric pockets (C1-C5) of tau. ADME profiling via SwissADME confirmed the compound's drug-likeness, CNS activity potential, and low toxicity risk. These findings support Dalfina as a promising lead compound for further experimental validation in tau-targeted Alzheimer's therapy.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mendis, L. G. (2025). In Silico Design and Molecular Docking of Dalfina: A Tau-Targeting Small Molecule for Alzheimer's Disease Therapy. Authorea Preprints. https://doi.org/10.22541/au.174897530.02602628/v1
Vancouver
Mendis LG. In Silico Design and Molecular Docking of Dalfina: A Tau-Targeting Small Molecule for Alzheimer's Disease Therapy. Authorea Preprints. 2025. doi:10.22541/au.174897530.02602628/v1.
BibTeX
@article{mendis2025-f4484f4b,
author = {Mendis, L. G.},
title = {{In Silico Design and Molecular Docking of Dalfina: A Tau-Targeting Small Molecule for Alzheimer's Disease Therapy}},
journal = {Authorea Preprints},
year = {2025},
doi = {10.22541/au.174897530.02602628/v1},
url = {https://doi.org/10.22541/au.174897530.02602628/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Dalfina was optimized to selectively bind hyperphosphorylated tau isoforms and demonstrated favorable physicochemical properties for blood-brain barrier (BBB) permeability.
- Molecular docking was performed using Autodock Vina and revealed binding affinities ranging from-5.1 to-6.2 kcal/mol at key allosteric pockets (C1-C5) of tau.
- These findings support Dalfina as a promising lead compound for further experimental validation in tau-targeted Alzheimer's therapy.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 19 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 12 of the 62 points we could judge it on, which is 19 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Authorea Preprints) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 12 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 12 of the 62 points we could judge it on is 19 out of 100. |
| Total | 19 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “phosphorylation”
388 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 388 tagged studies.